Targacept, Inc., a biopharmaceutical company, engages in the development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of nervous system and gastrointestinal/genitourinary diseases and disorders.
http://www.priceseries.com/trade/CBIO-Catalyst-Biosciences-Inc--stock-gains-46-percent-a-Trade-Record-by-priceSeries-2017091220171012.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments